Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies

Journal of Clinical Oncology

Volumn 29, Issue 10, 2011, Pages 1271-1279

  Yap, Timothy A ^a   Olmos, David ^a   Brunetto, Andre T ^a   Tunariu, Nina ^a   Barriuso, Jorge ^a   Riisnaes, Ruth ^a   Pope, Lorna ^a   Clark, Jeremy ^a   Futreal, Andrew ^a   Germuska, Michael ^a   Collins, David ^a   DeSouza, Nandita M ^a   Leach, Martin O ^a   Savage, Ronald E ^a   Waghorne, Carol ^a   Chai, Feng ^a   Garmey, Edward ^a   Schwartz, Brian ^a   Kaye, Stan B ^a   De Bono, Johann S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARQ 197; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; ENZYME INHIBITOR; ERLOTINIB; FOCAL ADHESION KINASE; SCATTER FACTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ALOPECIA; ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL EVALUATION; CONNECTIVE TISSUE DISEASE; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHAGIA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HOT FLUSH; HUMAN; HYPOKALEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MERKEL CELL; MERKEL CELL TUMOR; METABOLIC DISORDER; MUCOSA INFLAMMATION; NAUSEA; NICK END LABELING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PRURITUS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISEASE; SOLID TUMOR; STAINING; STOMACH CANCER; THROMBOCYTOPENIA; TONGUE DISEASE; TUMOR BIOPSY; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; APOPTOSIS; ARYL HYDROCARBON HYDROXYLASES; BIOPSY; ENDOTHELIAL CELLS; ENGLAND; FEMALE; FOCAL ADHESION KINASE 1; HUMANS; IN SITU NICK-END LABELING; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRROLIDINONES; QUINOLINES; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953885749     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.0367     Document Type: Article

References (40)

1. Comoglio PM, Giordano S, Trusolino L: Drug development of MET inhibitors: Targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:504-516, 2008 (Pubitemid 351767118)
2. Eder JP, Vande Woude GF, Boerner SA, et al: Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207-2214, 2009
3. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043, 2007 (Pubitemid 46799492)
4. Schmidt L, Duh FM, Chen F, et al: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73, 1997 (Pubitemid 27198158)
5. Lee JH, Han SU, Cho H, et al: A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19:4947-4953, 2000
6. Zhang YW, Su Y, Volpert OV, et al: Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A 100:12718-12723, 2003 (Pubitemid 37339965)
7. Rosen EM, Goldberg ID: Scatter factor and angiogenesis. Adv Cancer Res 67:257-279, 1995
8. Yap TA, de Bono JS: Targeting the HGF/c-Met axis: State of play. Mol Cancer Ther 9:1077-1079, 2010
9. Wen PY, Prados M, Schiff D, et al: Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). J Clin Oncol 28:181s, 2010 (suppl; abstr 2006)
10. Srinivasan R, Choueiri T, Vaishampayan U, et al: A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol 26:275s, 2008 (suppl; abstr 5103)
11. Kwak E, Camidge D, Clark J, et al: Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 27:148s, 2009 (suppl; abstr 3509)
12. Salgia R, Peterson AC, Bothos J, et al: Complete results from a phase 1a dose-escalation and dose-expansion study of single-agent MetMAb, a monovalent antagonist antibody to the receptor MET, administrated intravenously in patients with locally advanced or metastatic solid tumors. 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, April 17-21, 2010 (abstr 2774)
13. Munshi N, Jeay S, Li Y, et al: ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9:1544-1553, 2010
14. Porter J: Small molecule c-Met kinase inhibitors: A review of recent patents. Expert Opin Ther Pat 20:159-177, 2010
15. Underiner TL, Herbertz T, Miknyoczki SJ: Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates. Anticancer Agents Med Chem 10:7-27, 2010
16. Pan BS, Chan GK, Chenard M, et al: MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res 70:1524-1533, 2010
17. Kanome T, Kadofuku T, Yamaoka T, et al: The novel c-MET inhibitor, ARQ 197, shows additive growth-inhibitory effect with erlotinib through enhanced degradation of c-MET protein via ubiquitin/proteasome pathway. 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, April 17-21, 2010 (abstr 1639)
18. Chen CR, Szwaya J, Rojnuckarin A, et al: Combination studies of tyrosine kinase inhibitors (TKIs): Assessment of potential cytotoxic synergy of ARQ 197 with sorafenib or sunitinib. 100th Annual Meeting of the American Association for Cancer Research, San Diego, CA, April 18-22, 2009 (abstr 820)
19. Garcia A, Rosen L, Cunningham C, et al: Phase 1 study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose. J Clin Oncol 25:144s, 2007 (suppl; abstr 3525)
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982 (Pubitemid 13149996)
22. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm
23. Mekhail T, Rich T, Rosen L, et al: Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors. J Clin Oncol 27:158s, 2009 (suppl; abstr 3548)
24. Greenman C, Stephens P, Smith R, et al: Patterns of somatic mutation in human cancer genomes. Nature 446:153-158, 2007 (Pubitemid 46398669)
25. Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897-6904, 2004 (Pubitemid 39383039)
26. Strijbos MH, Verhoef C, Gratama JW, et al: On the origin of (CD105+) circulating endothelial cells. Thromb Haemost 102:347-351, 2009
27. d'Arcy JA, Collins DJ, Padhani AR, et al: Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: Analysis and visualization of dynamic contrast-enhanced MR imaging data. Radiographics 26:621-632, 2006
28. Tofts PS, Kermode AG: Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging: 1. Fundamental concepts. Magn Reson Med 17:357-367, 1991
29. Tofts PS, Brix G, Buckley DL, et al: Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 10:223-232, 1999 (Pubitemid 29463104)
30. Parker GJ, Roberts C, Macdonald A, et al: Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 56:993-1000, 2006 (Pubitemid 44691341)
31. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467, 1999 (Pubitemid 29517916)
32. Uehara Y, Minowa O, Mori C, et al: Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373:702-705, 1995
33. Takai K, Hara J, Matsumoto K, et al: Hepatocyte growth factor is constitutively produced by human bone marrow stromal cells and indirectly promotes hematopoiesis. Blood 89:1560-1565, 1997 (Pubitemid 27097448)
34. Rodriguez-Antona C, Ingelman-Sundberg M: Cytochrome P450 pharmacogenetics and cancer. Oncogene 25:1679-1691, 2006
35. Desta Z, Zhao X, Shin JG, et al: Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913-958, 2002 (Pubitemid 35168437)
36. Adjei A, Sosman J, Dy G, et al: A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors. J Clin Oncol 28:239s, 2010 (suppl 15s; abstr 3024)
37. Rowand JL, Martin G, Doyle GV, et al: Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 71:105-113, 2007 (Pubitemid 46238939)
38. Pantel K, Brakenhoff RH, Brandt B: Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8:329-340, 2008 (Pubitemid 351596394)
39. Olmos D, Arkenau HT, Ang JE, et al: Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): A single-centre experience. Ann Oncol 20:27-33, 2009
40. Schiller JH, Akerley WL, Brugger W, et al: Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 28:539s, 2010 (suppl; abstr LBA7502)